# CoV_PLE_concept_sets
covid PLE concept sets for Exposures

Currents sets to be developed 

## DMARDs

### Ts:
* [ ] Hydroxychloroquine (ingredient)
* [ ] Tocilizumab (ingredient)
* [ ] Baricitinib (ingredient)
### Cs: 
* [x] Methotrexate (ingredient)
* [x] Sulfasalazine (ingredient)

##Anti-HIV antiviral therapies

### Ts:
* [ ] Protease inhibitors [-navir] (class)
* [ ] Umifenovir (ingredient)
* [ ] Remdesivir (ingredient)
* [ ]	Lopinavir (ingredient) 
* [ ]	Ritonavir (ingredient)

### Cs: 
* [ ]	Integrase inhibitors (class) (includes raltegravir, elvitegravir, dolutegravir, bictegravir)
* [ ]	Non-nucleoside reverse transcriptase inhibitors (class) (included efavirenz, nevirapine, delavirdine, etravirine, rilpivirine, doravirine)

## Anti-Hepatitis C antiretroviral therapies
### Ts:
* [ ]	Hepatitis C virus NS3/4A protease inhibitors [–previr] (class)
* [ ]	Asunaprevir (ingredient)
* [ ]	Boceprevir (ingredient)
* [ ]	Grazoprevir (ingredient)
* [ ] Glecaprevir (ingredient)
* [ ]	Paritaprevir (ingredient)
* [ ]	Simeprevir (ingredient)
* [ ]	Telaprevir (ingredient)

### Cs:
* [ ]	Pegylated interferon (ingredient)
* [ ]	Ribavirin (ingredient)


## Drugs targeting the renin–angiotensin system
### Ts:
* [ ] ACE inhibitors (class)
* [ ] ARBs (class)
### Cs: 
* [ ] Thiazides and thiazide-like diuretics (class) 
* [ ] calcium channel blockers (class)



